Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:

SVB Securities Global Biopharma ConferenceFebruary 14, 20233:40 p.m. ET – fireside chat

H.C. Wainwright Cell Therapy Virtual ConferenceFebruary 28, 2023Time tbd – fireside chat

Cowen 43rd Annual Health Care ConferenceMarch 8, 20232:10 p.m. ET – industry panel discussion

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.[email protected]

You May Also Be Interested In

• Meritage Homes Announces Quarterly Cash Dividend
• Toledo Jeep Fest Caps Milestone 10th Year as Its Biggest, Most Celebrated Festival Yet
• Seafarer Exploration Enters Agreement With Tom McReynolds to Evaluate Known Shipwreck Site Near Naples